B. Riley Forecasts Harrow's FY2024 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW - Free Report) - Research analysts at B. Riley cut their FY2024 EPS estimates for Harrow in a note issued to investors on Wednesday, December 4th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($0.53) per share for the year, down from their prior forecast of $0.09. B. Riley has a "Buy" rating and a $69.00 price target on the stock. The consensus estimate for Harrow's current full-year earnings is $0.09 per share. B. Riley also issued estimates for Harrow's Q4 2024 earnings at $0.06 EPS, FY2025 earnings at $0.99 EPS, FY2026 earnings at $3.07 EPS and FY2027 earnings at $5.28 EPS.

Other research analysts also recently issued research reports about the stock. Lake Street Capital upped their target price on shares of Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, October 4th. Craig Hallum upped their price objective on Harrow from $45.00 to $65.00 and gave the company a "buy" rating in a research report on Friday, October 4th.

Harrow Stock Up 5.1 %

HROW traded up $1.90 during midday trading on Friday, reaching $39.32. The company's stock had a trading volume of 270,919 shares, compared to its average volume of 508,865. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The stock's 50-day moving average is $47.18 and its 200-day moving average is $35.07. Harrow has a 1 year low of $9.13 and a 1 year high of $59.23. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -39.81 and a beta of 0.69.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HROW. Private Capital Management LLC lifted its holdings in shares of Harrow by 7.8% during the 1st quarter. Private Capital Management LLC now owns 3,012,393 shares of the company's stock valued at $39,854,000 after buying an additional 217,896 shares during the period. Vanguard Group Inc. lifted its holdings in Harrow by 1.2% in the first quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company's stock valued at $24,208,000 after acquiring an additional 21,253 shares during the period. State Street Corp lifted its holdings in Harrow by 2.2% in the third quarter. State Street Corp now owns 730,973 shares of the company's stock valued at $32,865,000 after acquiring an additional 15,554 shares during the period. Geode Capital Management LLC grew its stake in shares of Harrow by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company's stock valued at $32,500,000 after purchasing an additional 3,960 shares during the period. Finally, Braidwell LP grew its stake in shares of Harrow by 47.9% during the 3rd quarter. Braidwell LP now owns 439,638 shares of the company's stock valued at $19,766,000 after purchasing an additional 142,450 shares during the period. Institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.